U.S. Biotech Stock News

Salesforce (NYSE:CRM) is powering Engine's shift to AI centric travel operations using Agentforce 360 and a Salesforce powered Slackbot. Engine now resolves 50% of its chat based customer support autonomously while reporting improved service quality. The agentic model is used to reduce handle times while maintaining governance, data privacy, and real time intelligence across travel workflows. For investors watching how large software vendors turn AI products into customer outcomes, this...

Investors may be wondering if Viper Energy at around US$46.50 is still offering value, or if most of the easy upside is already reflected in the price. The stock recently closed at US$46.50, with returns of 1.9% over 7 days, 3.6% over 30 days, 19.9% year to date and 25.6% over the last year. These moves have likely caught the attention of investors watching for shifts in risk and reward. Recent coverage has focused on Viper Energy's position within the US energy sector and how investors are...

HEICO disclosed that its subsidiaries 3D PLUS, Exxelia, and VPT previously supplied mission-critical electronic components for NASA’s Artemis II deep space mission, supporting key avionics and power systems across the launch platform. This involvement reinforces HEICO’s role as a specialized supplier in high-reliability space hardware, potentially broadening its opportunities in future government and commercial space programs. Next, we’ll examine how HEICO’s role in supplying...

Analyst sentiment shift puts Dave (DAVE) in focus Multiple analysts, including Citizens analyst Devin Ryan, have reiterated positive views on Dave (DAVE) while raising their price expectations, an event that has drawn fresh attention to the stock and its recent share move. See our latest analysis for Dave. The recent analyst optimism comes on top of a sharp 1-day share price return of 7.6% and a 1-year total shareholder return of around 1.8x, pointing to strong momentum supported by a very...

This article examines whether Paramount Skydance at US$11.67 could be a bargain or a value trap by focusing on what the current price might be implying about the stock. The share price has moved 7.9% over the last week and 22.8% over the last month. Year to date, the return sits at an 11.5% decline, and the 1-year return is 10.7%, set against a 45.7% decline over 3 years and a 67.8% decline over 5 years. Recent coverage has focused on the ongoing integration of Paramount and Skydance and...

New capsule collection puts Dillard's stock in focus Dillard's (DDS) has drawn fresh investor attention after introducing Cyd Morris x Gianni Bini, an exclusive limited-edition capsule collection that expands its contemporary womenswear and accessories offering across stores and online. See our latest analysis for Dillard's. The new capsule collection lands after a strong run for shareholders, with 1-year total shareholder return above 100%, even as the 90-day share price return of an 8.83%...

Recent share performance and earnings profile Novanta (NOVT) has attracted investor attention after a period of mixed share performance, with a month gain of 7.2% contrasted by a 5.1% decline over the past 3 months. At a last close of US$126.45 and a market value of about US$4.6b, the company reports annual revenue of US$980.6m and net income of US$53.8m. The reported annual revenue and net income growth rates are 6.3% and 33.9% respectively. See our latest analysis for Novanta. Recent moves...

BigBear.ai Holdings (BBAI) has refreshed its leadership team, appointing Jo Ann Bjornson as Chief Human Resources Officer and Alex Thompson as Chief Corporate Affairs Officer. These moves could shape how the company manages people and reputation. See our latest analysis for BigBear.ai Holdings. BigBear.ai Holdings' recent executive appointments arrive after a mixed period for the stock, with a 7.67% 1 day share price return and an 8.60% 7 day share price return contrasting with a 90 day share...

Silence Therapeutics plc ( NASDAQ:SLN ) insiders who purchased shares in the last 12 months were richly rewarded last...

We wouldn't blame MoonLake Immunotherapeutics ( NASDAQ:MLTX ) shareholders if they were a little worried about the fact...

If you are wondering whether Astronics at US$76.26 still offers value after a big run, the starting point is understanding what the current price actually reflects about the business. The stock has recorded returns of 4.7% over the last 7 days, 11.0% over 30 days, 34.7% year to date and 234.6% over the past year, with 3 year and 5 year returns of 379.6% and 342.9% respectively. This naturally raises questions about how much optimism is already priced in. Recent coverage around Astronics has...

On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleotide (ASO) platform to develop antisense therapeutics against multiple undisclosed RNA targets, with Alloy receiving an upfront payment plus potential milestones and tiered royalties. A key angle for investors is that this deal pairs Biogen’s neurological drug development expertise with a next-generation ASO platform specifically...

Sirius XM Holdings recently reported its latest quarterly results, with revenue remaining flat year on year while earnings per share slightly exceeded analyst expectations despite a miss on adjusted operating income. This mix of stable revenue and better-than-expected profitability has drawn attention to how effectively Sirius XM is managing costs and monetization in a highly competitive audio market. We’ll now examine how this earnings-per-share beat, despite flat revenue and an adjusted...

Amkor Technology (AMKR) is back on traders’ screens after a strong earnings release, with revenue, EPS, and adjusted operating income all ahead of analyst estimates and the share price reacting sharply. See our latest analysis for Amkor Technology. The stock’s strong earnings beat follows a powerful run, with a 30 day share price return of 33.81% and a 1 year total shareholder return of about 3.7x, suggesting momentum is still firmly building around Amkor Technology. If this kind of move has...

United Therapeutics recently announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to miroliverELAP, its investigational external liver assist device developed by Miromatrix to provide temporary support for acute liver failure patients using a bioengineered liver derived from decellularized porcine scaffolds and human donor cells. This RMAT designation, combined with earlier positive Phase 1 data for miroliverELAP and progress across United Therapeutics’...

What NiSource’s Recent Returns Tell You NiSource (NI) has drawn attention after a period where the stock showed a 0.3% gain over the past day, a 1.5% decline over the past week, and mixed performance over the month and past 3 months. See our latest analysis for NiSource. At a share price of US$47.37, NiSource shows a 90 day share price return of 8.8% and a year to date gain of 12.4%, while the 1 year total shareholder return of 25.0% points to momentum that has built over a longer period. If...

AerCap Holdings appointed Doug Parker as a Non Executive Director to its board, bringing in a former airline industry leader. The change follows the latest AGM, which included the retirement of Julian (Brad) Branch and the re appointment of several other directors. The moves indicate ongoing board refresh at NYSE:AER that could influence future oversight and decision making. AerCap Holdings, trading on the NYSE under ticker NYSE:AER, last closed at $147.24. The stock shows a 56.3% return...

For readers wondering whether First Solar at around US$195 has already run its course or still offers value, this article walks through what the current price might be implying about the stock. The share price has pulled back around 2.8% over the last week and 2.1% over the last month, but still reflects a 56.9% return over the past year and 133.4% over five years, alongside a 28.8% decline year to date and a 10.5% decline over three years. Recent headlines have focused on broad interest in...

Why recent results matter for Ross Stores (ROST) Ross Stores (ROST) has been in focus after strong quarterly results, steady same store sales growth, and a high return on invested capital, all of which have shaped a more positive tone among investors. See our latest analysis for Ross Stores. Ross Stores’ share price has shown firm upward momentum, with a 30 day share price return of 7.79% and a 1 year total shareholder return of 63.24%, indicating strong recent and longer term interest in the...

If you are wondering whether Prudential Financial's current share price reflects its true worth, starting with a clear look at valuation can help you decide how it fits in your portfolio. The stock last closed at US$99.42, with returns of 2.9% over 7 days, 6.7% over 30 days, a negative 12.7% year to date, 6.2% over 1 year, 31.5% over 3 years, and 29.1% over 5 years, giving you a mixed picture of recent and longer term performance. Recent moves in Prudential Financial's share price sit...

Why Expedia Group Is On Investors’ Radar Today Expedia Group (EXPE) is back on watchlists after recent share price moves, with the stock up over the past week and month but showing a negative return across the past 3 months and year to date. See our latest analysis for Expedia Group. This recent 1-day share price return of 3.57% and 7-day share price return of 8.67% sit against a weaker 90-day share price return of a 12.52% decline. The 1-year total shareholder return of 70.11% highlights how...

If you are wondering whether Intuitive Surgical at around US$468 per share is offering fair value or asking too much, this breakdown is designed to help you frame that question clearly. The stock has returned 1.3% over the last week, while the 30 day return sits at a 3.1% decline and the year to date return at a 16.7% decline, with the one year return at a 2.7% decline despite a 56.9% three year return and a 57.6% five year return. Recent attention on Intuitive Surgical has focused on its...

Wondering if Coca-Cola at around US$75.31 is fairly priced, expensive, or still offering value? This article breaks down what the current market tag might really mean for you. The stock is showing mixed recent returns, with a 2.6% decline over 7 days and a 3.2% decline over 30 days, alongside a 9.0% return year to date and 8.1% over the last year. These moves are playing out against a backdrop of ongoing attention on large, established consumer brands. Investors regularly reassess how much...

In April 2026, Stifel upgraded Texas Instruments after its March 5 announcement of a collaboration where Nvidia and Texas Instruments will combine AI compute with TI’s real-time control, sensing, and power technologies to advance humanoid robotics and AI applications. This partnership highlights how Texas Instruments’ analog and embedded chips may become more embedded in emerging AI and robotics ecosystems across data centers and edge devices. We’ll now examine how Texas Instruments’...